Orthocell appoints US-based distributors

Orthocell appoints US-based distributors

Fresh from receiving clearance from the Food and Drug Administration to distribute its nerve repair product Remplir in the US earlier this month, Murdoch-based Orthocell has appointed an initial four distributors.

StockTake: Orthocell to enter the US market

Regenerative medicine developer Orthocell (ASX:OCC) has appointed the first four US distributors for its flagship nerve repair product Remplir. The appointments follow FDA clearance for Remplir which landed earlier this month, and Orthocell are expecting first sales in the US very soon. Today, the US’ nerve repair market is valued at US$1.6 billion. Orthocell will tap this market through distributors in Michigan, Virginia, Colorado and Indiana. …

Orthocell sees US Remplir sales on immediate horizon as distro deal locked in

Orthocell (ASX:OCC) has locked in a U.S. distributor deal for its flagship product and biotech punter favourite Remplir, leaving the company confident U.S. sales are about to kick off. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. The company, up over +200% YoY as part of a recent wave of biotech hopefuls making strides with the FDA, has m…